DISC1, an oncogene, activates the GSK3β/β-catenin signaling to promote NSCLC growth, so it could be designed to be a novel anti-NSCLC therapeutic target (Wang et al., 2017), which means that HAL has the same mutation gene and differentiation process as NSCLC does. The gene discussed is GSK3B; the disease is non-small cell lung carcinoma.